Dixon Jonathan V. 4

What Happened Jonathan V. Dixon, General Counsel of Bionano Genomics (BNGO), was granted a derivative equity award covering 26,117 shares on February 2, 2026. The grant is reported as a zero-dollar acquisition (an option/award rather than an open-market purchase), so no cash was paid at grant.

Key Details

• Transaction date: 2026-02-02; Report filed: 2026-02-04 (Form 4 appears timely — filed within two business days).
• Transaction type/code: A (Award/Grant of a derivative instrument).
• Shares/units granted: 26,117; reported acquisition price: $0.00 (derivative award).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The option award vests monthly over 48 months beginning one month after the vesting commencement date; fully vested and exercisable on the four-year anniversary.

Context This was a standard equity award to an executive (not a market purchase or sale). Because it’s an option/award, it represents potential future ownership as the award vests — not immediate stock ownership or a cash transaction. Retail investors typically view grants as routine compensation; they don’t by themselves signal a buy/sell decision unless followed by exercises or open-market purchases/sales.